Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard Greil

Showing results (301-310 of 483) with videos related to

Pageof 49
Sort By:
Journal of Cancer Research and Clinical Oncology|July 21, 2022
Body composition dynamics and impact on clinical outcome in gastric and gastro-esophageal junction cancer patients undergoing perioperative chemotherapy with the FLOT protocolFlorian Huemer, Stefan Hecht, Bernhard Scharinger, et al.
Future Oncology (London, England)|March 20, 2026
AGMT mCRC Registry Third-Line and Beyond: a multicentric real-world platform with integrated imaging and biosample database for later-line metastatic colorectal cancerFlorian Huemer, Gudrun Piringer, Wolfgang Eisterer, et al.
British Journal of Cancer|September 28, 2019
Ixazomib-Thalidomide-Dexamethasone for induction therapy followed by Ixazomib maintenance treatment in patients with relapsed/refractory multiple myelomaHeinz Ludwig, Wolfram Poenisch, Stefan Knop, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 11, 2011
Impact of body mass index on the efficacy of endocrine therapy in premenopausal patients with breast cancer: an analysis of the prospective ABCSG-12 trialGeorg Pfeiler, Robert Königsberg, Christian Fesl, et al.
Haematologica|January 13, 2022
First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab <i>versus</i> chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trialCarol Moreno, Richard Greil, Fatih Demirkan, et al.
Annals of Hematology|May 21, 2021
Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the iLLUMINATE studyRichard Greil, Alessandra Tedeschi, Carol Moreno, et al.
Function (Oxford, England)|October 3, 2023
Inactivation of TRPM7 Kinase Targets AKT Signaling and Cyclooxygenase-2 Expression in Human CML CellsBirgit Hoeger, Wiebke Nadolni, Sarah Hampe, et al.
European Journal of Cancer (Oxford, England : 1990)|February 26, 2018
Clonal evolution and heterogeneity in metastatic head and neck cancer-An analysis of the Austrian Study Group of Medical Tumour Therapy study groupThomas Melchardt, Teresa Magnes, Clemens Hufnagl, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|February 24, 2021
Vinorelbine as substitute for vincristine in patients with diffuse large B cell lymphoma and vincristine-induced neuropathyStefan Hatzl, Florian Posch, Arwin Rezai, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 10, 2013
AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancerLuca Gianni, Gilles H Romieu, Michail Lichinitser, et al.
Pageof 49

Showing results (301-310 of 483) with videos related to

Sort By:
Pageof 49
Journal of Cancer Research and Clinical Oncology|July 21, 2022
Body composition dynamics and impact on clinical outcome in gastric and gastro-esophageal junction cancer patients undergoing perioperative chemotherapy with the FLOT protocolFlorian Huemer, Stefan Hecht, Bernhard Scharinger, et al.
Future Oncology (London, England)|March 20, 2026
AGMT mCRC Registry Third-Line and Beyond: a multicentric real-world platform with integrated imaging and biosample database for later-line metastatic colorectal cancerFlorian Huemer, Gudrun Piringer, Wolfgang Eisterer, et al.
British Journal of Cancer|September 28, 2019
Ixazomib-Thalidomide-Dexamethasone for induction therapy followed by Ixazomib maintenance treatment in patients with relapsed/refractory multiple myelomaHeinz Ludwig, Wolfram Poenisch, Stefan Knop, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 11, 2011
Impact of body mass index on the efficacy of endocrine therapy in premenopausal patients with breast cancer: an analysis of the prospective ABCSG-12 trialGeorg Pfeiler, Robert Königsberg, Christian Fesl, et al.
Haematologica|January 13, 2022
First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab <i>versus</i> chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trialCarol Moreno, Richard Greil, Fatih Demirkan, et al.
Annals of Hematology|May 21, 2021
Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the iLLUMINATE studyRichard Greil, Alessandra Tedeschi, Carol Moreno, et al.
Function (Oxford, England)|October 3, 2023
Inactivation of TRPM7 Kinase Targets AKT Signaling and Cyclooxygenase-2 Expression in Human CML CellsBirgit Hoeger, Wiebke Nadolni, Sarah Hampe, et al.
European Journal of Cancer (Oxford, England : 1990)|February 26, 2018
Clonal evolution and heterogeneity in metastatic head and neck cancer-An analysis of the Austrian Study Group of Medical Tumour Therapy study groupThomas Melchardt, Teresa Magnes, Clemens Hufnagl, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|February 24, 2021
Vinorelbine as substitute for vincristine in patients with diffuse large B cell lymphoma and vincristine-induced neuropathyStefan Hatzl, Florian Posch, Arwin Rezai, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 10, 2013
AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancerLuca Gianni, Gilles H Romieu, Michail Lichinitser, et al.
Pageof 49